Dr. Vandana Lal has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Vandana Lal, Promoter and Whole-Time Director of Dr. Lal Path Labs, has submitted a disclosure confirming that she along with other Promoter/Promoter Group/PAC members have NOT made any encumbrance (pledge) over company shares during the financial year ended March 31, 2026. The disclosure covers three key entities: (Hony) Brig. Dr. Arvind Lal (Promoter), Dr. Archana Lal Erdmann (Promoter Group), and Mr. Anjaneya Lal (Promoter Group). Additional entities like Pharmaceutical Private Limited, Central Clinical Laboratory, Genecode Health Private Limited, and Genecode Healthcare LLC are listed as part of the Promoter Group with nil shareholding. The filing also clarifies that Doon MRI Private Limited, though shown as part of the Promoter Group in the 2015 IPO document, does not qualify under current SEBI ICDR Regulations 2018.
This is a positive disclosure for investors as it confirms that promoters have not pledged their shares, reducing risk of forced selling. Clean promoter holdings with zero encumbrance indicate strong promoter commitment and lower hidden risk for minority shareholders.